Loading…
Bruker Corporation is projected to rise to $86.92 by 2027, a +35% move from its current price of $64.34. BRKR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $62.57 | $64.36 | $66.20 | +0.03% |
| Aug 2 | $61.86 | $64.38 | $67.00 | +0.06% |
| Aug 3 | $61.32 | $64.39 | $67.62 | +0.08% |
| Aug 4 | $60.88 | $64.41 | $68.15 | +0.11% |
| Aug 5 | $60.49 | $64.43 | $68.63 | +0.14% |
| Aug 6 | $60.14 | $64.45 | $69.06 | +0.17% |
| Aug 7 | $59.83 | $64.47 | $69.47 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $59.83 | $64.47 | $69.47 | +0.20% |
| Week 2 | $58.12 | $64.59 | $71.79 | +0.39% |
| Week 3 | $56.86 | $64.72 | $73.66 | +0.59% |
| Week 4 | $55.85 | $64.84 | $75.29 | +0.78% |
| Week 5 | $54.98 | $64.97 | $76.78 | +0.98% |
| Week 6 | $54.21 | $65.10 | $78.17 | +1.18% |
| Week 7 | $53.53 | $65.22 | $79.48 | +1.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscopy, preclinical imaging, biopharma and applied solutions, services and lifecycle support, integrated data solutions, and automation.
It also provides life science tools, innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. Bruker also offers portable analytical and bioanalytical detection systems, X-ray instruments, analytical tools for electron microscopes, handheld X-ray fluorescence spectrometry instruments, atomic force microscopy instrumentation, non-contact nanometer resolution topography, automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. Bruker provides advanced optical fluorescence microscopy instruments, transcriptional profiling and multiomic analysis services, superconducting materials and metallic low temperature superconductors, multifilament wires, and related products.
Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
Bruker Corporation (BRKR) is a healthcare sector company with a current price of $60.45 and a market cap of $9.2B, ranking 909. The stock trades around key moving averages, with a 50-day simple moving average of $55.33 and a 200-day simple moving average of $44.98. The price position is supportive of a bullish stance given the price level near these averages and the stock’s technical setup.
The long-term price outlook is positive based on the year-by-year forecast, which shows growing average prices into the late 2020s and beyond, with 2026 averaging $60.45 and rising to substantial levels by 2030, 2040, and 2050.
A major floor 47.6% below — a decisive break under it would weaken the trend.
The nearest floor, 14.9% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 10.0% above — clearing it would confirm fresh momentum.
Key BRKR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BRKR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $61.90 | Buy | $62.32 | Buy |
| MA 10 | $60.62 | Buy | $61.31 | Buy |
| MA 20 | $60.10 | Buy | $60.17 | Buy |
| MA 50 | $57.16 | Buy | $56.29 | Buy |
| MA 100 | $47.49 | Buy | $51.47 | Buy |
| MA 200 | $45.65 | Buy | $47.68 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.67 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 192.55 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.17 | Buy |
| ROC (12) | 7.54 | Buy |
| Bollinger %B (20,2) | 1.06 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.32 | Buy |
| Awesome (5,34) | 2.83 | Buy |
| Ultimate (7,14,28) | 63.32 | Neutral |
| Momentum (10) | 5.09 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 63.10 | Buy |
| ADX (14) | 16.99 | Neutral |
| ATR (14) | 1.64 | Info |
The 30-day technical picture shows bullish sentiment with a bullish tilt in the near term. RSI(14) is 60, indicating neutral-to-bullish momentum. The stock trades above the SMA50 of $55.33 and well above the SMA200 of $44.98, which supports a constructive trend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $32.76 | $64.34 | $92.38 | 0% | Neutral | |
| $69.10 | $86.92 | $115.74 | +35% | Bullish | |
| $82.30 | $106.60 | $147.53 | +66% | Bullish | |
| $88.12 | $116.94 | $166.78 | +82% | Bullish | |
| $96.58 | $130.93 | $191.49 | +104% | Bullish | |
| $132.24 | $182.79 | $273.27 | +184% | Bullish | |
| $154.92 | $218.05 | $332.45 | +239% | Bullish | |
| $168.77 | $241.61 | $374.97 | +276% | Bullish | |
| $193.29 | $281.22 | $443.63 | +337% | Bullish | |
| $195.85 | $289.38 | $463.48 | +350% | Bullish | |
| $339.10 | $537.46 | $917.12 | +735% | Bullish | |
| $730.23 | $1,306.48 | $2,444.47 | +19.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $32.76 | $64.34 | $75.14 | +0.00% |
| August 2026 | $56.26 | $66.08 | $79.46 | +2.71% |
| September 2026 | $55.71 | $65.99 | $80.46 | -0.13% |
| October 2026 | $57.34 | $68.40 | $84.30 | +3.64% |
| November 2026 | $60.20 | $72.22 | $89.80 | +5.59% |
| December 2026 | $61.11 | $73.71 | $92.38 | +2.06% |
Click any year to see its month-by-month BRKR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BRKR is projected to trade between $32.76 and $92.38, averaging $64.34 — a potential gain of 0% from today's $64.34. Price action looks broadly range-bound.
Bruker Corporation's 2027 outlook centres on $86.92, within a $69.10 to $115.74 range. That is up +35% on the projected 2026 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, BRKR could reach as high as $147.53, with a base case around $106.60 and support toward $82.30 — roughly +66% from $64.34. Momentum favours further upside here.
Expect BRKR to range from $88.12 to $166.78 through 2029. The $116.94 average target implies a +82% move from current prices. That is up +10% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The BRKR price prediction for 2030 points to an average of $130.93 (low $96.58, high $191.49) — a potential gain of +104% on today's $64.34. Momentum favours further upside here.
In 2031, BRKR is projected to trade between $132.24 and $273.27, averaging $182.79 — a potential gain of +184% from today's $64.34. That is up +40% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Bruker Corporation's 2032 outlook centres on $218.05, within a $154.92 to $332.45 range. That is up +19% on the projected 2031 average. That marks a +239% change versus current levels. Momentum favours further upside here.
By 2033, BRKR could reach as high as $374.97, with a base case around $241.61 and support toward $168.77 — roughly +276% from $64.34. Buyers look set to stay in control over this stretch.
Expect BRKR to range from $193.29 to $443.63 through 2034. The $281.22 average target implies a +337% move from current prices. That is up +16% on the projected 2033 average. Momentum favours further upside here.
The BRKR price prediction for 2035 points to an average of $289.38 (low $195.85, high $463.48) — a potential gain of +350% on today's $64.34. Buyers look set to stay in control over this stretch.
In 2040, BRKR is projected to trade between $339.10 and $917.12, averaging $537.46 — a potential gain of +735% from today's $64.34. That is up +86% on the projected 2035 average. Momentum favours further upside here.
Bruker Corporation's 2050 outlook centres on $1,306.48, within a $730.23 to $2,444.47 range. That is up +143% on the projected 2040 average. That marks a +19.3x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in BRKR today (≈ 15.542431 BRKR) could be worth
$20,305.91
+$19,305.91 (+1931%) by 2050 · US Dollar
Based on the average projected BRKR price of $1,306.48 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BRKRwould be worth at today's price.
$1,000 invested in BRKR on Jul 30, 2025 (≈ 24.449877 BRKR) would be worth
$1,573.11
+$573.11 (+57.3%) today · 1.57× · US Dollar
Based on a BRKR entry price of $40.9 vs. today's $64.34.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $62.15 | $1,035.24 | +3.5% |
| 1 month ago | $60.18 | $1,069.13 | +6.9% |
| 3 months ago | $36.79 | $1,748.84 | +74.9% |
| 6 months ago | $44.29 | $1,452.7 | +45.3% |
| 1 year ago | $40.9 | $1,573.11 | +57.3% |
| All time (5.0y) ago | $82.5 | $779.88 | -22.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BRKR forecast.
Our base-case forecast reaches $130.00 around 2030.
Implied market cap at $130.00: $19.79B
Across the multi-year forecast, the asset shows substantial upside potential. In 2026 the average price is $60.45 with ROI 0 and neutral sentiment. By 2027 the average price rises to $82.76 with ROI 36.9 and a bullish stance, and by 2028 the average is $101.35 with ROI 67.7.
The 2029 forecast puts the average at $110.88 and ROI 83.4, continuing the bullish trend toward 2030 where the average reaches $125.35 and ROI 107.4. The outlook stays bullish through 2040 with an average of $521.48 and ROI 762.7, and culminates in 2050 with an average of $1,271.78 and ROI 2003.9, supported by a strong bullish sentiment. These figures illustrate a persistent upside path but remain estimates, not guarantees, and carry inherent uncertainty and risk.
Tap a question to reveal the answer.
In 2030, the forecasted average price is $125.35, with a minimum of $92.13 and a maximum of $184.08, and ROI of 107.4, with a bullish sentiment.
The forecast shows a bullish outlook across multiple years from 2027 onward, with rising average prices and ROIs (e.g., 2027 avg $82.76, ROI 36.9; 2028 avg $101.35, ROI 67.7; 2029 avg $110.88, ROI 83.4; 2030 avg $125.35, ROI 107.4). Note that 2026 is neutral with avg $60.45 and ROI 0.
Yes. The 2028 forecast shows an average price of $101.35 and a maximum of $140.74, with 2029 avg $110.88, indicating movement past $100 in the forecast window.
The current price is $60.45 and the market cap is $9.2B, with a rank of 909.
For 2050, the forecasted minimum is $703.46, the average is $1,271.78, and the maximum is $2,396.40, with ROI 2003.9 and bullish sentiment.
Bruker Corporation Community Discussion
0Share your Bruker Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.